Future research should include a larger number of patients with knee osteoarthritis. SAN DIEGO — Results presented here showed intra-articular injections of platelet-rich plasma may be inferior ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...

Swiss pharma major Novartis has discontinued development of its experimental treatment QUC398 for knee osteoarthritis, ending ...

The Arthritis Knee Pain Centers (AKPC) and Dr. John Rush, its owner and Chief Executive Officer, face False Claims Act ...

The Feel Good Knees program is backed by a no-questions-asked, 60-day money-back guarantee. If users don't feel a measurable improvement in pain, mobility, or overall comfort, they can request a full ...

Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced multiple updates on its rapidly advancing clinical development ...

DelveInsight's “Musculoskeletal Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Avanos Medical, Inc. has gone through a transition period recently and its stock appears cheap with a low P/E ratio. Learn ...

Commitment to Efficiency and Margin Expansion. The Pacira Board and management team are committed to enhancing the company’s operational efficiency and expect to prioritize opportunities to drive ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...